The Janssen Biotech unit of Johnson & Johnson will co-develop and market Theravance Biopharma's pan-Janus kinase inhibitor TD-1473 and related backup compounds, which are indicated to treat inflammatory intestinal diseases, including Crohn's disease and ulcerative colitis. Under the terms of the deal, Theravance will get $100 million upfront and another $200 million if Janssen decides to continue the deal after two planned studies.
Janssen, Theravance to collaborate on intestinal-disease therapies
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.